Esperion Therapeutics, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$13Mgeneral payments (2019-2025)
$36Kresearch payments (2019-2025)
46,508clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| John Isaac | Houston, TX | Interventional Cardiology | $355,721.14 |
| William Cromwell | Raleigh, NC | Family Medicine | $328,715.54 |
| Matthew Budoff | Torrance, CA | Cardiovascular Disease | $302,517.05 |
| Payal Kohli | Aurora, CO | Cardiovascular Disease | $295,971.16 |
| Denzil Moraes | Baton Rouge, LA | Interventional Cardiology | $200,321.69 |
| Jaime Burkle | Gainesville, GA | Cardiovascular Disease | $182,495.01 |
| Jonathan Lown | Commack, NY | Internal Medicine | $171,655.49 |
| Yili Huang | Elmhurst, NY | Interventional Cardiology | $142,334.39 |
| Dean Karalis | Philadelphia, PA | Cardiovascular Disease | $137,032.26 |
| Brett Nowlan | Bloomfield, CT | Cardiovascular Disease | $125,802.92 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.